PD Dr. med. Dr. rer. nat. Udo Siebolts

Academic education

2005 – 2011 University of Cologne, Center for molecular medicine, graduate study molecular medicine (PhD)

1998 – 2004 University of Cologne, study of medicine

1992 – 1998 University of Cologne and Oldenburg, study of Biology (Diploma)

Scientific degrees

2019 Habilitation, clinical pathology, University Hospital of Halle (Saale)

2011 PhD (MD-PhD) thesis, Center for molecular medicine (ZMMK) University of Cologne

2006 MD thesis, University of Cologne, Prof. Dr. Thiele

Scientific career

2021 – present Managing senior pathologist, University Hospital Cologne

2020 – present Medical Director of the medical care center for molecular diagnostics DiaVZ, Leipzig

2014 – 2021 Head of diagnostic molecular pathology, University Hospital Halle (Saale)

2014 – 2021 Deputy director and managing senior clinical pathologist, University Hospital of Halle (Saale)

2012 – 2013 Managing senior clinical pathologist, University Hospital of Leipzig

2008 – 2010 Cologne-Fortune Scholarship, University of Cologne

2008 – 2012 Physician, University Hospital of Leipzig

2004 – 2008 Physician, University Hospital of Cologne

2011 PhD (MD-PhD) thesis, Center for molecular medicine (ZMMK) University of Cologne


Since 2022 Board Member of the German society of pathology

2020 – 2021 Speaker of the regional centre of the national network of genomic medicine (nNGM)
Since 2019 Editorial Board Member, Breast Care

2017 Head of organization committee of the yearly meeting of German molecular pathologists

Since 2017 Speaker of the molecular pathology working group, German pathologist association (DGP)

Since 2015 Committee Member of the AWMF- Clinical Practice Guidelines S3; thyroid pathology

Contact Information

Dr. med. Dr. rer. nat. Udo Siebolts SFB1399
Dr. med. Dr. rer. nat. Udo Siebolts

Senior pathologist and medical head of molecular diagnostic pathology

University Hospital and Medical School

Institute for Pathology UoC, Cologne

Curriculum Vitae (CV)

10 most relevant publications

  • Koehler VF, Adam P, Fuss CT, Jiang L, Berg E, Frank-Raue K, Raue F, Hoster E, Knösel T, Schildhaus HU, Negele T, Siebolts U, Lorenz K, Allelein S, Schott M, Spitzweg C, Kroiss M; German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands. Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors-A Retrospective Multi-Center Registry Analysis. Cancers (Basel). 2022 Jul 13;14(14):3405. doi: 10.3390/cancers14143405.PMID: 35884466
  • Wille D, Heinzelmann J, Kehlen A, Lütgehetmann M, Nörz DS, Siebolts U, Mueller A, Karrasch M, Hofmann N, Viestenz A, Börgel M, Kuhn F, Viestenz A. New Safety Aspects in Corneal Donation-Studies on SARS-CoV-2-Positive Corneal Donors. J Clin Med. 2022 Jun 9;11(12):3312. doi: 10.3390/jcm11123312.PMID: 35743381
  • Oezkan F, Byun WY, Loeffler C, Siebolts U, Diessel L, Lambrecht N, Eisenmann S. Crown-Cut Endobronchial Ultrasound Guided Transbronchial Aspiration Needle: First Real-World Experiences. J Clin Med. 2021 Dec 29;11(1):163. doi: 10.3390/jcm11010163.PMID: 35011904
  • Kaatzsch P, Lorenz K, Horn LC, Wickenhauser C, Schmid KW, Dralle H, Siebolts U. Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer. Machens Surgery. 2022 Feb;171(2):360-367. doi: 10.1016/j.surg.2021.07.035. Epub
  • Siemanowski J, Schömig-Markiefka B, Buhl T, Haak A, Siebolts U, Dietmaier W, Arens N, Pauly N, Ataseven B, Büttner R, Merkelbach-Bruse S. Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches. Cancers (Basel). 2021 Mar 12;13(6):1268. doi: 10.3390/cancers13061268.PMID: 33809329
  • Heydt C, Rehker J, Pappesch R, Buhl T, Ball M, Siebolts U, Haak A, Lohneis P, Büttner R, Hillmer AM, Merkelbach-Bruse S. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. Sci Rep. 2020 Jul 9;10(1):11387. doi: 10.1038/s41598-020-68394-4.
  • Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, Pfarr N, Siebolts U, Hummel M, Herold S, Andreas J, Zoche M, Tögel L, Rempel E, Maas J, Merino D, Stewart M, Zaoui K, Schlesner M, Glimm H, Fröhling S, Allen J, Horst D, Baretton G, Wickenhauser C, Tiemann M, Evert M, Moch H, Kirchner T, Büttner R, Schirmacher P, Jung A, Haller F, Weichert W, Dietel M. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol. 2020 Jul;15(7):1177-1189. doi: 10.1016/j.jtho.2020.01.023. Epub 2020 Feb 29.
  • Fiorentzis M, Viestenz A, Siebolts U, Seitz B, Coupland SE, Heinzelmann. The Potential Use of Electrochemotherapy in the Treatment of Uveal Melanoma: In Vitro Results in 3D Tumor Cultures and In Vivo Results in a Chick Embryo Model. J Cancers (Basel). 2019 Sep1;11(9):1344. doi: 10.3390/cancers11091344.
  • Vogiatzi F, Brandt DT, Schneikert J, Fuchs J, Grikscheit K, Wanzel M, Pavlakis E, Charles JP, Timofeev O, Nist A, Mernberger M, Kantelhardt EJ, Siebolts U, Bartel F, Jacob R, Rath A, Moll R, Grosse R, Stiewe T. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8433-E8442. doi: 10.1073/pnas.1612711114. Epub 2016 Dec 12
  • Siebolts U, Lange T, Niederwieser D, Wickenhauser C. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy. J Clin Pathol. 2010 Apr;63(4):370-2. doi: 10.1136/jcp.2009.069773